BackZentalis Pharmaceuticals Overview

Zentalis Pharmaceuticals Receivables

Zentalis Pharmaceuticals's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Zentalis Pharmaceuticals Receivables History

Loading

Zentalis Pharmaceuticals vs. peers: Receivables Comparison

Loading

Zentalis Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Zentalis Pharmaceuticals (ZNTL) FAQ

Zentalis Pharmaceuticals (ZNTL) currently reports a receivables of $0 as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Zentalis Pharmaceuticals's receivables history and peer comparisons.

Zentalis Pharmaceuticals's receivables changed from $0 to $0 (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zentalis Pharmaceuticals reported $0 in receivables as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zentalis Pharmaceuticals, and consider following ZNTL for alerts when major investors trade the stock.

Zentalis Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZNTL with unrelated industries.